Patents Represented by Attorney, Agent or Law Firm David A. Muthard
  • Inhibitors of farnesyl-protein transferase
    Patent number: 6093737
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: December 23, 1997
    Date of Patent: July 25, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Neville J. Anthony, Robert P. Gomez, Lekhanh O. Tran, Steven D. Young
  • Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
    Patent number: 6080870
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: October 1, 1998
    Date of Patent: June 27, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Neville J. Anthony, Robert P. Gomez, Gerald E. Stokker, John S. Wai, Theresa M. Williams, Wasyl Halczenko, John H. Hutchinson, Steven D. Young, Kelly M. Solinsky
  • Inhibitors of farnesyl-protein transferase
    Patent number: 6077853
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: April 28, 1999
    Date of Patent: June 20, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Samuel L. Graham, Steven D. Young
  • Inhibitors of farnesyl-protein transferase
    Patent number: 6051574
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: February 10, 1999
    Date of Patent: April 18, 2000
    Assignee: Merck & Co., Inc.
    Inventor: Neville J. Anthony
  • Inhibitors of farnesyl-protein transferase
    Patent number: 6015817
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: December 4, 1997
    Date of Patent: January 18, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Wasyl Halczenko, Craig A. Stump
  • Inhibitors of farnesyl-protein transferase
    Patent number: 6001835
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: March 25, 1997
    Date of Patent: December 14, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Christopher J. Dinsmore, Theresa M. Williams
  • Conjugates useful in the treatment of prostate cancer
    Patent number: 5998362
    Abstract: Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA), hydrophilic oligopeptide blocking groups and known cytotoxic agents are disclosed. Such conjugates are useful in the treatment of prostatic cancer and benign prostatic hypertrophy (BPH).
    Type: Grant
    Filed: September 9, 1997
    Date of Patent: December 7, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Dong-Mei Feng, Victor M. Garsky, Raymond E. Jones, Jenny M. Wai
  • Inhibitors of farnesyl-protein transferase
    Patent number: 5981562
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: January 21, 1997
    Date of Patent: November 9, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Christopher J. Dinsmore, George D. Hartman
  • Inhibitors of farnesyl-protein transferase
    Patent number: 5977134
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: December 4, 1997
    Date of Patent: November 2, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Terrence M. Ciccarone, Wasyl Halczenko, John H. Hutchinson, William C. Lumma, Jr., Gerald E. Stokker, Craig A. Stump, Theresa M. Williams
  • Inhibitors of farnesyl-protein transferase
    Patent number: 5972966
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherpeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: December 4, 1997
    Date of Patent: October 26, 1999
    Assignee: Merck & Co., Inc.
    Inventor: S. Jane deSolms
  • Inhibitors of farnesyl-protein transferase
    Patent number: 5972984
    Abstract: The present invention comprises low molecular weight peptidyl compounds that inhibit the farnesyl-protein transferase. Furthermore, these compounds differ from the mono- or dipeptidyl analogs previously described as inhibitors of farnesyl-protein transferase in that they do not have a thiol moiety. The lack of the thiol offers unique advantages in terms of improved pharmacokinetic behavior in animals, prevention of thiol-dependent chemical reactions, such as rapid autoxidation and disulfide formation with endogenous thiols, and reduced systemic toxicity. Further contained in this invention are chemotherapeutic compositions containing these farnesyl transferase inhibitors and methods for their production.
    Type: Grant
    Filed: October 29, 1997
    Date of Patent: October 26, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Neville J. Anthony, Jeffrey M. Bergman, S. Jane deSolms, Chrisopher J. Dinsmore, Robert P. Gomez, Suzanne C. MacTough, Kelly M. Solinsky, Theresa M. Williams
  • Inhibitors of farnesyl-protein transferase
    Patent number: 5972942
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: March 27, 1997
    Date of Patent: October 26, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Dong D. Wei, Theresa M. Williams
  • Inhibitors of farnesyl-protein transferase
    Patent number: 5968965
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: January 21, 1997
    Date of Patent: October 19, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Christopher J. Dinsmore, George D. Hartman
  • Inhibitors of farnesyl-protein transferase
    Patent number: 5965578
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: March 25, 1997
    Date of Patent: October 12, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Samuel L. Graham, Theresa M. Williams, John S. Wai
  • Conjugates useful in the treatment of prostate cancer
    Patent number: 5948750
    Abstract: Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA) and known cytotoxic agents are disclosed. Such conjugates are useful in the treatment of prostatic cancer and benign prostatic hypertrophy (BPH).
    Type: Grant
    Filed: October 14, 1997
    Date of Patent: September 7, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Victor M. Garsky, Deborah Defeo-Jones, Dong-Mei Feng
  • Inhibitors of farnesyl-protein transferase
    Patent number: 5939557
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: March 25, 1997
    Date of Patent: August 17, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Neville J. Anthony, Robert P. Gomez, Kelly M. Solinsky
  • Inhibitors of farnesyl-protein transferase
    Patent number: 5939439
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: December 22, 1997
    Date of Patent: August 17, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Neville J. Anthony, Samuel L. Graham, Lekhanh O. Tran, Ian M. Bell, S. Jane deSolms, Robert P. Gomez, Michelle Sparks Kuo, William C. Lumma, Jr., Debra S. Perlow, Anthony W. Shaw, John S. Wai, Steven D. Young
  • Inhibitors of farnesyl-protein transferase
    Patent number: 5932590
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: December 4, 1997
    Date of Patent: August 3, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Terrence M. Ciccarone, S. Jane deSolms
  • Inhibitors of farnesyl-protein transferase
    Patent number: 5925651
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: April 1, 1997
    Date of Patent: July 20, 1999
    Assignee: Merck & Co., Inc.
    Inventor: John H. Hutchinson
  • Inhibitors of farnesyl-protein transferase
    Patent number: 5922883
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: March 26, 1997
    Date of Patent: July 13, 1999
    Assignee: Merck & Co., Inc.
    Inventor: John H. Hutchinson